SCHEMBL743837

SCHEMBL743837

CN1[C@@H]2CC[C@H]1C[C@@H](Nc1cncc(-c3ccc4cc[nH]c4c3)c1)C2

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIP4K2A P48426 2/20 0.48
PIP4K2B P78356 2/20 0.48
KCNH2 Q12809 6/20 0.43
CHRNA7 P36544 5/20 0.43
KAT2B Q92831 1/20 0.41
GSK3B P49841 2/20 0.38
DYRK1A Q13627 2/20 0.38
KDM1A O60341 1/20 0.38
MAOA P21397 1/20 0.38
MAOB P27338 1/20 0.38
BRAF P15056 1/20 0.37
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
CYP3A4 P08684 1/20 0.37
HPGD P15428 1/20 0.37
TSHR P16473 1/20 0.37
HSD17B10 Q99714 1/20 0.37
BRD4 O60885 2/20 0.36
ATAD2 Q6PL18 1/20 0.36
MPO P05164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL743838 1.00 PIP4K2A (0.48) PIP4K2APIP4K2BKCNH2CHRNA7KAT2B
SCHEMBL748602 0.93 PIP4K2A (0.47) PIP4K2APIP4K2BKCNH2CHRNA7KAT2B
SCHEMBL748603 0.93 PIP4K2A (0.47) PIP4K2APIP4K2BKCNH2CHRNA7KAT2B
SCHEMBL743913 0.83 KCNH2 (0.47) PIP4K2APIP4K2BKCNH2CHRNA7KAT2B
SCHEMBL743914 0.83 KCNH2 (0.47) PIP4K2APIP4K2BKCNH2CHRNA7KAT2B
SCHEMBL747644 0.80 HPGDS (0.53) PIP4K2APIP4K2BKCNH2CHRNA7GSK3B
SCHEMBL747645 0.80 HPGDS (0.53) PIP4K2APIP4K2BKCNH2CHRNA7GSK3B
SCHEMBL744853 0.80 CHRNA7 (0.48) KCNH2CHRNA7GSK3BDYRK1AKDM4E
SCHEMBL748444 0.80 CHRNA7 (0.48) KCNH2CHRNA7GSK3BDYRK1AKDM4E
SCHEMBL748443 0.78 NPC1 (0.44) PIP4K2APIP4K2BKCNH2CHRNA7KAT2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2431368-A1 CNS active fused bicycloheterocycle substituted azabicyclic alkane derivatives Abbott Laboratories (US) 2012-03-21 EP claimed
EP-2018380-B1 Cns active fused bicycloheterocycle substituted azabicyclic alkane derivatives ABBOTT LAB (US) 2011-10-19 EP claimed
US-20110178121-A1 Methods for Treating Pain ABBOTT LABORATORIES (US) 2011-07-21 US claimed
US-7872017-B2 Fused bicycloheterocycle substituted azabicyclic alkane derivatives ABBOTT LABORATORIES (US) 2011-01-18 US claimed
US-20100305089-A1 Fused Bicycloheterocycle Substituted Azabicyclic Alkane Derivatives ABBOTT LABORATORIES (US) 2010-12-02 US claimed
US-20080045539-A1 FUSED BICYCLOHETEROCYCLE SUBSTITUTED AZABICYCLIC ALKANE DERIVATIVES ABBVIE INC. 2008-02-21 US claimed
US-8940762-B2 Methods for treating pain ABBVIE INC. (US) 2015-01-27 US disclosed
EP-2431368-B1 CNS active fused bicycloheterocycle substituted azabicyclic alkane derivatives ABBVIE BAHAMAS LTD (BS) 2014-08-27 EP disclosed
EP-2431368-A1 CNS active fused bicycloheterocycle substituted azabicyclic alkane derivatives Abbott Laboratories (US) 2012-03-21 EP disclosed
EP-2018380-B1 Cns active fused bicycloheterocycle substituted azabicyclic alkane derivatives ABBOTT LAB (US) 2011-10-19 EP disclosed
US-20110178121-A1 Methods for Treating Pain ABBOTT LABORATORIES (US) 2011-07-21 US disclosed
US-7872017-B2 Fused bicycloheterocycle substituted azabicyclic alkane derivatives ABBOTT LABORATORIES (US) 2011-01-18 US disclosed
US-20100305089-A1 Fused Bicycloheterocycle Substituted Azabicyclic Alkane Derivatives ABBOTT LABORATORIES (US) 2010-12-02 US disclosed
US-20080045539-A1 FUSED BICYCLOHETEROCYCLE SUBSTITUTED AZABICYCLIC ALKANE DERIVATIVES ABBVIE INC. 2008-02-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045539-A1 FUSED BICYCLOHETEROCYCLE SUBSTITUTED AZABICYCLIC ALKANE DERIVATIVES MALT1, BMP2, ALKBH2 PIP4K2A 1509/4885PIP4K2B 1580/4885KCNH2 708/4885
US-20100305089-A1 Fused Bicycloheterocycle Substituted Azabicyclic Alkane Derivatives MALT1, BMP2, ALKBH2 PIP4K2A 1509/4885PIP4K2B 1580/4885KCNH2 708/4885
US-20110178121-A1 Methods for Treating Pain CHRNA7, CHRNA3, CHRNA5 PIP4K2A 3629/4885PIP4K2B 3742/4885KCNH2 183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.